PDCD1 and melanoma: Next, we investigated in vivo cDC1 reprogramming as monotherapy or in combination with either anti-PD-1 or anti-CTLA-4 using B16, B2905 and the additional melanoma model YUMM1.7, which is resistant to ICB and also depends on cDC1 availability (11, 24, 26).